Evaluation of clinical and inflammatory profile in opioid addiction patients with comorbid pain: Results from a multicenter investigation

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 2239-2247

  Dennis, Brittany B ^a   Constantine Samaan, M ^a   Bawor, Monica ^a   Paul, James ^a   Plater, Carolyn ^b   Pare, Guillaume ^a   Worster, Andrew ^c   Varenbut, Michael ^b   Daiter, Jeff ^b   Marsh, David C ^b,d   Desai, Dipika ^e   Thabane, Lehana ^a,f,g   Samaan, Zainab ^a,e  

^a MCMASTER UNIVERSITY   (Canada)

^b Ontario Addiction Treatment Centres   (Canada)

^c HAMILTON GENERAL HOSPITAL   (Canada)

^d NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Brief pain inventory; CCL2; IFN ; Inflammatory markers; Interleukins; Methadone maintenance treatment; Opioid dependence; TNF

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; METHADONE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); OPIATE ADDICTION; PAIN; PROTEIN BLOOD LEVEL; URINALYSIS;

EID: 84938696927     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S72785     Document Type: Article

References (36)

1. UNODC. World Drug Report; 2010. Available from: http://www.unodc.org/unodc/en/data-and-analysis/WDR-2010.html. Accessed: September 2, 2014.
2. Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936-1943.
3. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289(18):2370-2378.
4. Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005;113(3):340-346.
5. Trafton JA, Oliva EM, Horst DA, Minkel JD, Humphreys K. Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment. Drug Alcohol Depend. 2004;73(1):23-31.
6. Barry DT, Bernard MJ, Beitel M, Moore BA, Kerns RD, Schottenfeld RS. Counselors’ experiences treating methadone-maintained patients with chronic pain: a needs assessment study. J Addict Med. 2008;2(2): 108-111.
7. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction. 2007;102(2):289-300.
8. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy. 2003;23(6):802-805.
9. Cao X, Wu Z, Li L, et al. Mortality among methadone maintenance clients in China: a six-year cohort study. PLoS One. 2013;8(12):e82476.
10. Bohnert AS, Ilgen MA, Trafton JA, et al. Trends and regional variation in opioid overdose mortality among veterans health administration patients, Fiscal Year 2001 to 2009. Clin J Pain. 2014;30(7):605-612.
11. Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013;2013:480739.
12. Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2012;87(1):10-20.
13. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6): 918-934.
14. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev. 2002;82(4): 981-1011.
15. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis. 2010;37(3): 534-541.
16. Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol. 2012;12(1):55-61.
17. Gruber HE, Hoelscher GL, Ingram JA, Hanley EN Jr. Genome-wide analysis of pain-, nerveand neurotrophin -related gene expression in the degenerating human annulus. Mol Pain. 2012;8(1):63.
18. Koch A, Zacharowski K, Boehm O, et al. Nitric oxide and proinflammatory cytokines correlate with pain intensity in chronic pain patients. Inflamm Res. 2007;56(1):32-37.
19. Barry DT, Beitel M, Joshi D, Schottenfeld RS. Pain and substancerelated pain-reduction behaviors among opioid dependent individuals seeking methadone maintenance treatment. Am J Addict. 2009;18(2): 117-121.
20. Ilgen MA, Trafton JA, Humphreys K. Response to methadone maintenance treatment of opiate dependent patients with and without significant pain. Drug Alcohol Depend. 2006;82(3):187-193.
21. Samaan Z, Bawor M, Dennis B, et al. Genetic influence in methadone dose and response to treatment in patients undergoing Methadone Maintenance Treatment (MMT) for opioid addiction: a pilot study. JNeuropsychiatr Dis Treat. 2014;10:1503-1508.
22. Marques-Vidal P, Bochud M, Bastardot F, et al. Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (CoLaus study). PLoS One. 2011;6(6):e21002.
23. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine. 2000;12(11):1712-1716.
24. Skeppholm M, Wallen NH, Blomback M, Kallner A. Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations? Clin Chem Lab Med. 2008;46(8): 1175-1179.
25. BIORAD Laboratories Inc. Bio-Plex™ Cytokine Assay. US patent 5,981,180; 6,046,807; 6,057,107. Available from http://www.bio-rad.com/webroot/web/pdf/lsr/literature/BULLETIN_10008318A.pdf. Accessed October 24, 2014.
26. NOVA Systems. Inventor; iMDx TM. Available from: http://www.novxsystems.com/novx/myweb.php?hls=10024. Accessed October 24, 2014.
27. Harrell, FE Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001. [Corrected edition, January 10, 2001].
28. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808.
29. Barry D, Sullivan B, Petry NM. Comparable efficacy of contingency management for cocaine dependence among African American, Hispanic, and White methadone maintenance clients. Psychol Addict Behav. 2009;23(1):168-174.
30. Tsuda M, Masuda T, Kitano J, Shimoyama H, Tozaki-Saitoh H, Inoue K. IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain. Proc Natl Acad Sci USA. 2009;106(19): 8032-8037.
31. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24(8):450-455.
32. Tsuda M, Inoue K, Salter MW. Neuropathic pain and spinal microglia: a big problem from molecules in “small” glia. Trends Neurosci. 2005; 28(2):101-107.
33. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6(7):521-532.
34. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10(11):1361-1368.
35. Cuellar JM, Golish SR, Reuter MW, et al. Cytokine evaluation in individuals with low back pain using discographic lavage. Spine J. 2010; 10(3):212-218.
36. Hutchinson MR, Coats BD, Lewis SS, et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun. 2008;22(8):1178-1189.